Table 2.

Association of Baseline and Follow‐Up Weighted Day‐Night SBPV (per mm Hg Increase) With Mortality

SBPV	All‐Cause Mortality, HR (95% CI)	Cardiovascular Mortality, HR (95% CI)
At baseline
Model 1	1.20 (1.12–1.28), P<0.001	1.26 (1.15–1.39), P<0.001
Model 2	1.19 (1.10–1.28), P<0.001	1.24 (1.12–1.36), P<0.001
At follow‐up
Model 1	1.12 (1.05–1.19), P<0.001	1.15 (1.05–1.25), P=0.002
Model 2	1.11 (1.04–1.18), P=0.002	1.11 (1.02–1.22), P=0.017

Model 1: HR adjusted for age, sex, smoking, drinking, history of previous heart disease, diabetes, raised cholesterol, low HDL (high‐density lipoprotein) cholesterol, and estimated glomerular filtration rate at baseline and in‐trial use of either angiotensin‐converting enzyme inhibitors or diuretics and number of antihypertensive drugs. Model 2: model 1 adjusted for corresponding mean ambulatory systolic blood pressure (baseline/follow‐up). HR indicates hazard ratio; SBPV, systolic blood pressure variability.